People · Operator
Named in public records as an officer, director or promoter · active 2013–2016 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Moderna LLC | — | Pharmaceuticals | Growth/Late | $691.1M | $16.2B | 2013 |
| Moderna Therapeutics, Inc. | — | Biotechnology | Growth/Late | $451.4M | $19.2B | 2016 |
| Lysosomal Therapeutics, Inc. | — | Biotechnology | Series B | $38.0M | $39.7M | 2014 |
Henri Termeer at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Henri Termeer on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 2 | 36 |
| Noubar Afeyan | 2 | 9 |
| Robert Carpenter | 2 | 5 |
| Lorence Kim | 2 | 5 |
| Lee Babiss | 2 | 5 |
| Stephane Bancel | 2 | 4 |
| John Mendlein | 2 | 4 |
| PETER HUTT | 2 | 4 |
| Bruce Booth | 1 | 12 |
| Clay Thorp | 1 | 10 |
| Daniel Geffken | 1 | 6 |
| Steven E. Hall | 1 | 4 |
| BERNARD DAVITIAN | 1 | 4 |
| Carole Neuchterlein | 1 | 3 |
| Peter Wirth | 1 | 3 |
| Carole Nuechterlein | 1 | 2 |
| James Kasinger | 1 | 2 |
| Theo Melas-Kyriazi | 1 | 2 |
| Bruce L Booth | 1 | 2 |
| Stephen Hoge | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.